{"preliminary_commentary":{"by_channel":{"x_thread":18},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06203210\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"IDeate-Lung02","nct_id":"NCT06203210","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ideate-lung02-nct06203210. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IDeate-Lung02","arms":[{"description":"Participants will be randomized to receive 12 milligrams per kilogram (mg/kg) I-DXd, intravenously (IV), as monotherapy on Day 1 of each 21-day cycle, once every 3 weeks (Q3W), until clinical or radiologic evidence of progression of disease determined by the investigator, unacceptable toxicity, withdrawal of informed consent, death, loss to follow-up, or other treatment discontinuation criteria are met as specified in the protocol.","label":"Ifinatamab deruxtecan (I-DXd)","type":"EXPERIMENTAL"},{"description":"Participants will be randomized to receive topotecan or lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label (indicated dose and frequency), until a treatment discontinuation criteria are met as specified in the protocol.","label":"Treatment of Physician's Choice (TPC)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2029-12-01","type":"ESTIMATED"},"conditions":["Small Cell Lung Cancer"],"enrollment":{"count":540,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ifinatamab deruxtecan","otherNames":["I-DXd"],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"},{"name":"Amrubicin","otherNames":[],"type":"DRUG"},{"name":"Lurbinectedin","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-06","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-01-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"From the date of randomization to the date of death due to any cause, up to approximately 3.7 years"}],"references":[{"citation":"Owonikoko TK, Byers L, Cheng Y, Hayashi H, Paz-Ares L, Perol M, Hu H, Qian M, Garcia CR, Godard J, Tang M, Rudin CM. IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. Future Oncol. 2025 Oct;21(25):3275-3282. doi: 10.1080/14796694.2025.2565995. Epub 2025 Oct 7.","pmid":"41055143","type":"DERIVED"}],"start_date":{"date":"2024-05-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06203210"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ideate-lung02-nct06203210"}